GenrAb will present antibody therapy data and company updates at IC³ Conference in Arlington, TX, on October 3rd.

GenrAb expands leadership team with Martin Devenport as COO and Dr. Jonghee Han as a specialist in neurology.

GenrAb wins two prestigious Golden Tickets from Boehringer Ingelheim and Otsuka, securing lab space for antibody development.

GenrAb expands exclusive license with UTSW, adding over 250 anti-neuronal antibodies to its growing pipeline.

GenrAb secures US patents for its lead antibody TGM-010, advancing neuroprotective therapy development.

GenrAb wins 2023 North Texas Therapeutics Innovator of the Year for pioneering antibody therapy at Innovation Days.

GenrAb selects BioLabs @ Pegasus Park, Dallas, as its HQ for antibody therapy development and expansion.